受注:045-509-1970 |
技術サポート:[email protected] 平日9:00〜18:00 1営業日以内にご連絡を差し上げます |
Synonyms | N/A | Storage (From the date of receipt) |
3 years -20°C powder 1 years -80°C in solvent |
|
化学式 | C17H16ClN3O |
|||
分子量 | 313.78 | CAS No. | 1056901-62-2 | |
Solubility (25°C)* | 体外 | DMSO | 62 mg/mL (197.59 mM) | |
Water | Insoluble | |||
Ethanol | Insoluble | |||
* <1 mg/ml means slightly soluble or insoluble. * Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations. |
製品説明 | AT13148 is an oral, ATP-competitive, multi-AGC kinase inhibitor with IC50 of 38 nM/402 nM/50 nM, 8 nM, 3 nM, and 6 nM/4 nM for Akt1/2/3, p70S6K, PKA, and ROCKI/II, respectively. Phase 1. |
---|---|
in vitro | AT13148, as a multi-AGC kinase inhibitor, potently inhibits proliferation with GI50 values of 1.5 to 3.8 μM across a selected panel of cancer cell lines with deregulation of PI3K-AKT-mTOR or RAS-RAF pathways. In PTEN-deficient MES-SA cells, AT13148 also inhibits AKT and p70S6K signaling. [1] |
in vivo | AT13148 (50 mg/kg p.o.) markedly inhibits the activity of both AKT and p70S6K AGC kinases, and subsequently exhibits marked antitumor effects in human tumor xenografts. [1] |
キナーゼアッセイ | In vitro kinase assays | |
---|---|---|
AT13148 is assayed against 40 kinases and the percentage inhibition at 10 μM of AT13148 is determined. Individual IC50 values are measured for selected kinases using ATP concentrations equivalent to the Km for each enzyme. | ||
細胞アッセイ | 細胞株 | MES-SA, MES-SA/Dx5, BT474, HCT-116, A549, PC3, SK-BR-3, MCF7, U87MG, MDA-MB-468, DU-145, and SK-OV-3 cell lines |
濃度 | ~10 μM | |
反応時間 | 72 hours or 96 hours | |
実験の流れ | Cytotoxicity is determined using a 72 h Alamar Blue assay or a 96 h SRB assay. |
|
動物実験 | 動物モデル | Athymic mice bearing MES-SA, BT474, or PC3 tumor xenografts |
投薬量 | ~50 mg/kg | |
投与方法 | p.o. |
Data from [Data independently produced by , , Biochem Biophys Res Commun, 2016, 478(1):330-6.]
Therapeutic targeting of tumor spheroids in a 3D microphysiological renal cell carcinoma-on-a-chip system [ Neoplasia, 2023, 10.1016/j.neo.2023.100948] | PubMed: 37944353 |
Immunogenic Death of Hepatocellular Carcinoma Cells in Mice Expressing Caspase-Resistant ROCK1 Is Not Replicated by ROCK Inhibitors [ Cancers (Basel), 2022, 14(23)5943] | PubMed: 36497425 |
A preclinical pipeline to evaluate migrastatics as therapeutic agents in metastatic melanoma [ Br J Cancer, 2021, 10.1038/s41416-021-01442-6] | PubMed: 34172930 |
DAPL1 is a novel regulator of testosterone production in Leydig cells of mouse testis [ Sci Rep, 2021, 11(1):18532] | PubMed: 34535743 |
The Global Phosphorylation Landscape of SARS-CoV-2 Infection [ Cell, 2020, 182(3):685-712.e19] | PubMed: 32645325 |
The Global Phosphorylation Landscape of SARS-CoV-2 Infection [ Cell, 2020, 182(3):685-712.e19] | PubMed: 32645325 |
Myosin II Reactivation and Cytoskeletal Remodeling as a Hallmark and a Vulnerability in Melanoma Therapy Resistance. [ Cancer Cell, 2020, 37(1):85-103] | PubMed: 31935375 |
MKI-1, a Novel Small-Molecule Inhibitor of MASTL, Exerts Antitumor and Radiosensitizer Activities Through PP2A Activation in Breast Cancer [ Front Oncol, 2020, 10:571601] | PubMed: 33117702 |
Mapping phospho-catalytic dependencies of therapy-resistant tumours reveals actionable vulnerabilities. [ Nat Cell Biol, 2019, 21(6):778-790] | PubMed: 31160710 |
LncRNA HAND2-AS1 overexpression inhibits cancer cell proliferation in melanoma by downregulating ROCK1. [ Oncol Lett, 2019, 18(2):1005-1010] | PubMed: 31423160 |
長期の保管のために-20°Cの下で製品を保ってください。
人間や獣医の診断であるか治療的な使用のためにでない。
各々の製品のための特定の保管と取扱い情報は、製品データシートの上で示されます。大部分のSelleck製品は、推薦された状況の下で安定です。製品は、推薦された保管温度と異なる温度で、時々出荷されます。長期の保管のために必要とされてそれと異なる温度で、多くの製品は、短期もので安定です。品質を維持するが、夜通しの積荷のために最も経済的な貯蔵状況を用いてあなたの送料を保存する状況の下に、製品が出荷されることを、我々は確実とします。製品の受領と同時に、製品データシートの上で貯蔵推薦に従ってください。